Health X's record quarter masks strategy reversals on debt and branded-generic conflict
Revenue hits ₹400 cr in Q1, but management's about-face on capital and channel conflict undercut the FY30 vision
The numbers
- FY26 revenue rose 18% to ₹1,283 cr; EBITDA loss narrowed to ₹65 cr from ₹79 cr.
- Q1FY27 revenue tracking at ₹400 cr, a historic best quarterly print.
- ₹424 cr warehouse capex announced, partially funded by ₹154 cr in bank loans.
- FY30 revenue target of ₹6,000 cr split into ₹4,000 cr B2B and ₹2,000 cr B2C.
Management's story
- FY30 target of ₹6,000 cr reaffirmed, with EBITDA margin 5% and PAT margin 4%.
- FY27 EBITDA margin target of 1% reaffirmed.
- JITHO private-label generics gaining traction with 30-40% margins.
- Gross margin expanded 100 bps to 7.5% for FY26.
“The total capex planned for this expansion is 234 crores. Out of that, we plan to take 154 crores in bank loans and deploy around 100 crores from the treasury.”
— Health X management, Jun 2026 call
Where they diverge
The narrative of no external capital for five years is contradicted by a ₹154 cr bank loan for warehouse expansion. Similarly, after denying any conflict between generic and branded products, management now admits the JITHO transition 'caused some disturbance' in branded sales. These reversals don't negate the operational improvement, but they strain trust in the path to ₹6,000 cr revenue by FY30.
The full read
Health X's operational turnaround is real. Q1FY27 revenue of ₹400 cr is a record, and FY26 EBITDA loss narrowed to ₹65 cr. But the forward story has two credibility gaps. Six months ago, management ruled out external capital for five years; now it's taking ₹154 cr in bank loans. It also denied any conflict between generic JITHO and branded medicines, then blamed JITHO for disturbing branded sales. The FY30 target of ₹6,000 cr requires consistent strategy and capital discipline. The numbers are improving, but the narrative keeps changing. Trust will hinge on whether management sticks to the 1% EBITDA margin target for FY27 and delivers on debt-funded capex without derailing the balance sheet. Ambition is not execution.
What we're watching
- FY27 EBITDA margin achievement against the 1% target — first proof point due by Q2FY27 results.
- JITHO-branded sales normalization timeline: management expects it by year-end.
- Debt servicing: ₹154 cr loans added to a debt-free balance sheet; cash flow from operations must cover interest.
- Warehouse capex execution: ₹424 cr spend while still loss-making at EBITDA level.